Loading...
Loading...
ACADIA Pharmaceuticals
ACAD announced
that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou
Ruvo Center for Brain Health, presented detailed results today from
ACADIA's pivotal Phase III -020 Study with pimavanserin in patients with
Parkinson's disease psychosis at the Emerging Science session of the 65th
American Academy of Neurology (AAN) Annual Meeting. The analysis of the
full data set from the Phase III -020 Study showed robust and consistent
efficacy of pimavanserin across a wide array of study measures and
confirmed the positive top-line results previously reported.
Pimavanserin met the primary endpoint
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in